Entrectinib May Be Effective, Well Tolerated Against ROS1-, NTRK-Positive Cancers
Integrated analyses showed entrectinib to be both effective and well tolerated in patients with rare ROS1 and NTRK gene fusions.
Related Articles
S09 E01 Tumor-Agnostic Therapies: Is The TAPUR Study Right For You? – Our MBC Life
For our Season 9 opening episode, we’re learning about agnostic treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the TAPUR Study. You may wonder,…
Tumor-Agnostic Therapies: Is The TAPUR Study Right For You? — Our MBC Life
For our Season 9 opening episode, we’re learning about agnostic treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the TAPUR Study. You…
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study | JCO Precision Oncology
PURPOSE Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients…
Why Evidence Generation Should Matter to Payers and How They Can Help
This Special Communication discusses the current clinical trials system, examines why payers should support evidence generation, and suggests potential avenues for collaboration.
Why Evidence Generation Should Matter to Payers and How They Can Help
This Special Communication discusses the current clinical trials system, examines why payers should support evidence generation, and suggests potential avenues for collaboration.
A call to action to advance patient‐focused and decentralized clinical trials
This commentary is a call to action for a concerted commitment and effort to transform clinical trials and enable people with cancer to participate in…
Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study | JCO Precision Oncology
PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in…
Bringing the Human Factor to the “Last Mile” of AI-Assisted Clinical Decisions
This article will appear in the June 2024 issue of Evidence-Based Oncology.
JCO Precision Oncology
ORIGINAL REPORTS Apr 02, 2024 ORIGINAL REPORTS Feb 21, 2024 ORIGINAL REPORTS Feb 21, 2024 ORIGINAL REPORTS Feb 14, 2024 ORIGINAL REPORTS Dec 14, 2023…
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
PURPOSE Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with…